Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03495817 · ClinicalTrials.gov registry record · Phase 2
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
A Phase 2 study of Androgenetic Alopecia, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 3
- Study locations
NCT03495817 is a Phase 2 study of Androgenetic Alopecia that has completed, run by Aclaris Therapeutics. The registered enrollment target is 31 participants, below the 163-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (81% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03495817, a Phase 2 study of Androgenetic Alopecia, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 3
- Study locations
Study Summary
Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.
Conditions Studied
Interventions
- DRUG ATI-50002
Study Locations (3)
Colorado
- Aclaris Investigational Site - Denver
Oregon
- Aclaris Investigational Site - Portland
Texas
- Aclaris Investigational Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-03-22 |
| Est. Completion | 2019-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03495817
The ClinicalTrials.gov registry entry for NCT03495817 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 163-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (81% lower). The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Androgenetic Alopecia appearing as the primary indexed condition, and to 1 intervention - of which ATI-50002 is the first listed.
NCT03495817 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Oregon, Texas.
Frequently Asked Questions
What is clinical trial NCT03495817 about?
NCT03495817 is a clinical study titled "A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution". Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.
What is the current status of trial NCT03495817?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2018-03-22. Estimated completion is 2019-10-30.
What conditions does trial NCT03495817 study?
This clinical trial studies the following conditions: Androgenetic Alopecia.
What interventions are being tested in trial NCT03495817?
The interventions under investigation include: ATI-50002 (DRUG).
Who is sponsoring clinical trial NCT03495817?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03495817 being conducted?
This trial has 3 study locations across Colorado, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of VDPHL01 in Males and Females With AGA
ACTIVE NOT RECRUITING · Phase 2
-
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of VDPHL01 in Males With AGA
ACTIVE NOT RECRUITING · Phase 2
-
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
COMPLETED · Phase 2
-
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)
COMPLETED · Phase 2
-
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.